Year None20242023202220212020 Jun 26, 2024 Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology Jun 03, 2024 Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference May 07, 2024 Lyell Immunopharma to Participate in BofA Securities Health Care Conference May 06, 2024 Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 Mar 05, 2024 Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting Feb 28, 2024 Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 Feb 26, 2024 Lyell Immunopharma Announces Participation in March Investor Conferences Jan 03, 2024 Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference